Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FHGU6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $66,337
Award facts
- Contract value 100% obligated
- $66,336.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $66,336.52 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of STELARA 90 mg/ml syringes. The delivery order, issued on December 16, 2025, with an ultimate completion date of January 8, 2026, carries no set-aside designation, indicating DMS Pharmaceutical Group competed successfully in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has been registered as a federal contractor since 2001 and maintains a robust product portfolio spanning branded and generic pharmaceuticals, biologics, vaccines, and specialty medical products critical to military medical operations. The company's PPV-G GEN V contract, valued at up to $499,999,999 through December 2036, positions it as a regional prime vendor capable of supplying diverse pharmaceutical requirements across DoD healthcare systems globally. STELARA, an immunosuppressant biologic agent, represents the type of specialized pharmaceutical product the company routinely delivers through the prime vendor contract structure to support ongoing military medical supply needs.
Quick answers
Who was awarded contract SPE2DR26FHGU6?
SPE2DR26FHGU6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FHGU6 worth?
The government has obligated $66,337 on SPE2DR26FHGU6.
Is contract SPE2DR26FHGU6 an order under another contract?
Yes. SPE2DR26FHGU6 is a delivery order under SPE2DR25D9244, an indefinite delivery contract.
Was contract SPE2DR26FHGU6 competed?
The extent of competition for SPE2DR26FHGU6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award